Can Regenerative Products Repair Knee Cartilage? What Current Research Shows
- LeNae Goolsby
- 2 hours ago
- 10 min read
Knee cartilage damage can make everyday life feel smaller. Stairs become a negotiation. Exercise becomes something you used to do. Even getting out of a chair can remind you that your knee is no longer moving the way it once did.
For years, patients with cartilage loss were often told to manage the pain until the joint became bad enough for surgery. Regenerative medicine offers a more proactive conversation: Can we improve the environment inside and around the joint, support the body’s healing response, and help the knee function better?
At Infinite Health Integrative Medicine Center in Metairie, we believe regenerative medicine can be a valuable option for appropriately selected patients. We have seen patients experience meaningful progress in the areas that matter most—moving more comfortably, returning to activities they had given up, and feeling hopeful about their bodies again.
Those results are why we are strong believers in regenerative medicine. They are also why we take patient selection, diagnosis, product quality, and realistic goal-setting seriously.
The Short Answer: Can Regenerative Medicine Help Damaged Knee Cartilage?
Current research is encouraging. Regenerative procedures may support a healthier joint environment, influence inflammatory and cellular signaling, and improve pain and function in some patients. Certain human studies have also reported favorable changes in cartilage thickness, volume, or quality on MRI.
The science is still evolving, and results differ according to the diagnosis, severity of damage, procedure, product, and patient. No treatment can guarantee that normal cartilage will grow back. But the absence of a guarantee does not mean regenerative medicine has no value.
For many patients, the most meaningful outcome is not a perfect MRI. It is being able to walk farther, sleep better, return to exercise, work without constant discomfort, or postpone making a more invasive treatment decision while preserving function.
Why Regenerative Medicine Is So Promising for Knee Pain
Traditional treatments often focus on temporarily reducing pain or inflammation. Regenerative medicine takes a different approach by attempting to influence the biological environment associated with injury, inflammation, and tissue health.
Depending on the procedure, proposed mechanisms may include:
Supporting cell-to-cell communication
Modulating inflammatory activity
Encouraging a more favorable healing response
Supporting the tissues surrounding and stabilizing the joint
Improving the conditions in which rehabilitation and movement occur
Researchers are continuing to study how these effects may translate into pain relief, improved function, and structural changes within the joint.
This distinction matters because knee osteoarthritis is not simply a missing layer of cartilage. It can also involve the bone beneath the cartilage, menisci, ligaments, tendons, joint lining, muscle weakness, alignment, and stability. The best results come from evaluating the knee as a whole rather than treating one MRI phrase.
What Does “Cartilage Repair” Mean?
Patients and researchers may use the word repair to describe different outcomes:
Reduced pain or stiffness
Improved mobility and physical function
Less swelling or inflammatory activity
A measurable change in cartilage thickness or volume
Improved cartilage composition on advanced MRI
Filling a focal defect with repair tissue
Restoring durable cartilage that performs like the original tissue
These outcomes are related, but they are not identical. A knee can feel and function significantly better without a dramatic change on imaging. Likewise, a small MRI change may not fully reflect how a patient feels.
At Infinite Health, the patient’s lived result matters. Imaging can be useful, but the larger question is whether treatment helps the patient reclaim meaningful parts of life.
What the Research Shows About Prolotherapy
Dextrose prolotherapy is one of the most established regenerative procedures used for musculoskeletal pain. It involves injecting a concentrated dextrose solution into or around painful joint structures to stimulate a localized healing response.
Clinical trials and systematic reviews have reported improvements in knee osteoarthritis pain, stiffness, and function. In a randomized controlled trial published in the Annals of Family Medicine, patients receiving dextrose prolotherapy experienced clinically meaningful improvement that continued through 52 weeks.
Prolotherapy may be especially relevant when pain involves not only the joint surface but also the ligaments, tendons, or other structures contributing to stability and movement.
Research has not established that prolotherapy reliably rebuilds normal hyaline cartilage. Its value should therefore be measured by the complete clinical response—including pain, mobility, function, and quality of life—not by a cartilage-regrowth claim alone.
What Cell-Based Research Tells Us About Cartilage
Mesenchymal stromal cells, commonly abbreviated as MSCs, are being studied because of their potential effects on inflammation, immune activity, cell signaling, and the joint environment.
Human studies have evaluated preparations derived from bone marrow, adipose tissue, placental tissue, and umbilical-cord tissue.
Several studies have produced encouraging findings:
A 2023 placebo-controlled trial of allogeneic adipose-derived MSCs reported improvement in pain and function along with slight increases in tibial and femoral cartilage thickness on MRI.
Some systematic reviews have found favorable clinical or radiological outcomes after stromal cell-based injections compared with other nonsurgical treatments.
A randomized trial of culture-expanded umbilical-cord-derived MSCs reported significant improvements in pain and function among treated patients.
Not every trial has demonstrated structural change, and reviews differ in their conclusions. That is expected in a developing field where cell source, dose, processing, delivery, patient selection, and outcome measures vary substantially.
The responsible takeaway is not that the treatment “does not work.” It is that the evidence is promising but product-specific, and broad claims should never replace an individualized evaluation.
Where Wharton’s Jelly–Derived Products Fit
Wharton’s Jelly is the connective tissue surrounding the blood vessels within the umbilical cord. It contains a complex extracellular matrix and naturally occurring structural and signaling components that have made it an important area of regenerative research.
Products described as Wharton’s Jelly–derived can differ according to donor screening, processing, preservation, testing, and final composition. They should not automatically be described as stem-cell products unless the cellular contents have been specifically verified.
This does not diminish their potential. It means the discussion should center on the exact product being used, what it contains, how it is handled, and what evidence reasonably applies to it.
Infinite Health’s approach is not based on a generic “stem cell” label. It is based on matching the procedure and product to the patient’s diagnosis, history, goals, and overall treatment plan.
What About Exosomes and Cartilage Repair?
Exosomes are extracellular vesicles that participate in cell-to-cell communication. They can carry proteins, lipids, and genetic material involved in signaling processes throughout the body.
Laboratory and animal studies have generated considerable interest in whether exosomes may help regulate inflammation, protect cartilage-producing cells, and support tissue recovery. This is one of the most exciting areas in regenerative research.
Human orthopedic research is still early. A 2024 placebo-controlled trial of one placental MSC-derived extracellular-vesicle preparation did not find a significant advantage in symptoms or MRI cartilage findings at six months. That result applies to the specific product, dose, protocol, and patient group studied; it does not answer every question about extracellular-vesicle therapies.
There are currently no FDA-approved exosome products. Patients considering an exosome-based treatment should receive a transparent explanation of the proposed use, evidence, potential risks, and regulatory status.
Why Product Quality and Patient Selection Matter
Regenerative medicine is not one treatment, and “knee pain” is not one diagnosis. Two patients with similar MRI reports may have very different sources of pain and very different treatment needs.
Factors that may influence the plan include:
Whether the problem is osteoarthritis, a focal cartilage defect, tendon or ligament injury, meniscus damage, or referred pain
The degree and location of cartilage loss
Joint alignment and stability
Strength, mobility, and gait
Previous treatments and surgeries
Overall health, medications, and healing capacity
The exact regenerative procedure and product under consideration
The patient’s goals and willingness to participate in rehabilitation
A regenerative procedure should not be treated as a one-size-fits-all injection. The evaluation, treatment technique, aftercare, and rehabilitation strategy all help shape the outcome.
Does Cartilage Have to Regrow for Treatment to Be Successful?
No. Cartilage is important, but it is not the only measure of a successful outcome.
Most patients are not seeking a scientifically interesting MRI. They want to move with less pain, stay active, work, travel, play with their grandchildren, or return to the activities that make them feel like themselves.
Meaningful goals may include:
Walking or standing longer
Using stairs more comfortably
Sleeping with fewer pain interruptions
Improving range of motion
Returning to exercise or recreation
Reducing reliance on pain-management strategies when medically appropriate
Feeling more stable and confident on the knee
These outcomes should be documented before treatment and reassessed over time. A patient can experience a meaningful clinical result even when the science cannot prove that normal cartilage was recreated.
Are There Established Surgical Cartilage-Repair Options?
Yes. Selected focal cartilage defects may be treated with orthopedic procedures such as microfracture, osteochondral grafting, or MACI.
MACI is an FDA-approved, two-stage surgical treatment in which a patient’s own cartilage cells are grown on a collagen membrane and implanted into a symptomatic full-thickness knee-cartilage defect. It is different from an office-based regenerative injection and is not intended for every patient with generalized osteoarthritis.
This distinction reinforces an important point: the right treatment depends on whether a patient has a focal defect, widespread arthritis, instability, malalignment, or another source of pain. Some patients may be better candidates for regenerative care, some for cartilage-restoration surgery, and others for a coordinated conservative plan.
What the FDA Status Means for Patients
FDA approval is specific to a product and its intended use. The FDA states that regenerative medicine products marketed as stem cells, Wharton’s Jelly, umbilical-cord products, orthobiologics, and exosomes have not been approved to treat orthopedic conditions such as knee osteoarthritis or knee pain.
This regulatory status should be disclosed clearly. It does not erase the published research or the meaningful results individual patients may experience. It means patients should understand what is being proposed and make an informed decision based on the exact product, available evidence, potential benefits, limitations, and risks.
The Infinite Health Approach to Regenerative Knee Care
Infinite Health does not begin with the assumption that every painful knee needs the same injection. The process begins with understanding what is driving the pain and what the patient wants to regain.
An individualized plan may include:
Review of symptoms, history, prior treatment, and imaging
Evaluation of joint function, stability, and movement
Selection of the most appropriate regenerative procedure when indicated
Clear expectations about recovery and follow-up
Rehabilitation, strength, and mobility support
Coordination with orthopedic or other medical care when appropriate
We are pro-regenerative medicine because we have seen what can happen when the right patient receives the right treatment with the right expectations. The goal is not to sell a miracle. The goal is to create the strongest possible opportunity for a meaningful result.
Regenerative medicine represents an exciting and increasingly studied option for people with knee cartilage damage and osteoarthritis.
Research suggests that regenerative approaches may improve pain and function, influence the joint environment, and, in some studies, produce favorable cartilage findings on MRI. Prolotherapy, Wharton’s Jelly–derived products, and exosome-based approaches work differently and should be evaluated on their own merits.
Science has not established guaranteed cartilage regrowth, but that is not the only outcome that matters. For the right patient, better movement, less pain, improved function, and a return to meaningful activities can be life-changing.
Find Out Whether Regenerative Medicine May Be Right for Your Knee
If knee pain is limiting your work, exercise, travel, or daily life, you do not have to wait until your only conversation is about surgery.
Schedule a free discovery call with an Infinite Health wellness coordinator to discuss your knee concerns, previous treatment, and goals. Virtual consultations may be available for an initial history and records review when clinically appropriate and permitted based on your location; an in-person examination or procedure may still be required.
The discovery call is not a medical visit and does not include diagnosis, treatment recommendations, or prescribing.
Frequently Asked Questions
Can regenerative medicine help knee cartilage damage?
Regenerative medicine may help selected patients by supporting the joint environment and improving pain or function. Some studies also report favorable MRI cartilage changes, although results vary by product, protocol, and patient.
Can stem cells regrow knee cartilage?
Certain cell-based studies have reported cartilage changes on MRI, but reliable restoration of normal knee cartilage has not been established. “Stem cell therapy” is also too broad a term unless the exact cell product is identified.
Is Wharton’s Jelly the same as stem cells?
No. Wharton’s Jelly is umbilical-cord connective tissue. The contents of a final product depend on how it is processed and tested. A Wharton’s Jelly–derived product should not automatically be called a stem-cell product.
Can exosomes help knee arthritis?
Exosomes are being studied for their potential effects on inflammation and cell signaling. The research is promising, but human orthopedic evidence remains early and there are currently no FDA-approved exosome products.
Can prolotherapy help knee osteoarthritis?
Clinical studies have reported improvements in pain, stiffness, and function after dextrose prolotherapy. Results vary, and it should not be presented as guaranteed cartilage regrowth.
Does treatment have to regrow cartilage to be worthwhile?
No. A meaningful improvement in pain, mobility, stability, sleep, or activity can be valuable even without proof that normal cartilage has regrown.
Can Infinite Health evaluate my knee virtually?
An initial history and records review may be possible virtually when permitted by location and clinical circumstances. Knee pain often requires an in-person examination, imaging review, or procedure.
Medical and Regulatory Review Note
This article is educational and is not a substitute for medical advice, diagnosis, or treatment. Individual outcomes vary. Product composition, manufacturing, FDA status, and applicable investigational requirements must be verified before publication and before clinical use. The article requires physician and regulatory review because evidence and legal status are product- and indication-specific.
Sources
U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies.
U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.
Rabago D, et al. Dextrose Prolotherapy for Knee Osteoarthritis: A Randomized Controlled Trial. Annals of Family Medicine. 2013.
Wee TC, et al. Dextrose Prolotherapy in Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Journal of Clinical Orthopaedics and Trauma. 2021.
Sadri B, et al. Allogeneic Adipose-Derived Mesenchymal Stromal Cells for Knee Osteoarthritis: A Phase II Randomized Placebo-Controlled Trial. Stem Cell Research & Therapy. 2023.
Matas J, et al. Umbilical Cord-Derived Mesenchymal Stromal Cells for Knee Osteoarthritis. Stem Cells Translational Medicine. 2019.
Dhillon J, et al. Stromal Cell-Based Injection Therapies for Knee Osteoarthritis: A Systematic Review of Level I Randomized Controlled Trials. Journal of ISAKOS. 2025.
Bolandnazar NS, et al. Placental Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Knee Osteoarthritis. BMC Musculoskeletal Disorders. 2024.
U.S. Food and Drug Administration. MACI: Autologous Cultured Chondrocytes on Porcine Collagen Membrane.
American Academy of Orthopaedic Surgeons. Articular Cartilage Restoration.
Comments